

This is a provisional PDF only. Copyedited and fully formatted version will be made available soon.

Authors: Ali M. A. Al-Kufaishi, Noor J.T. Al-Musawi

Article type: Original Article

Received: 7 May 2025

Accepted: 19 June 2025

Published online: 9 September 2025

eISSN: 2544-1361

Eur J Clin Exp Med

doi: 10.15584/ejcem.2025.4.10

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our authors we are providing this early version of the manuscript. The manuscript will undergo copyediting and typesetting. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Elevated estrogen receptor beta and oxidative stress in postmenopausal women with ovarian cancer

Ali M. A. Al-Kufaishi ¹, Noor J.T. Al-Musawi ²

¹ Department of Medical Laboratory Techniques, College of Health and Medical Techniques, Al-Furat Al-Awsat Technical University, Kufa, Iraq

² DNA Research Center, University of Babylon, Babylon, Iraq

Corresponding author: Ali M. A. Al-Kufaishi, e-mail: kuh.ali@atu.edu.iq

ORCID

AMAA-K: <https://orcid.org/0000-0002-8091-7577>

NJTA-M: <https://orcid.org/0009-0005-9933-8427>

ABSTRACT

Introduction and aim. Ovarian cancer in postmenopausal women is associated with hormonal dysregulation and oxidative stress. This study investigates the relationship between estrogen receptor beta (ER β), selected reproductive hormones, and oxidative stress markers in women with ovarian cancer compared to healthy controls. To our knowledge, this is one of the first studies to evaluate these parameters in an integrated way, offering new insights into the pathophysiological mechanisms underlying postmenopausal ovarian cancer.

Material and methods. Blood samples were collected from 45 postmenopausal women with ovarian cancer immediately after diagnosis to be compared with 45 healthy women. ER β and some hormones were evaluated using an enzyme-linked immunosorbent assay. Chemiluminescence immunoassays and miniVIDAS, while spectrophotometric methods were used to evaluate variables associated with oxidative stress.

Results. The results show a significant increase in beta estrogen receptor values for women with ovarian cancer 12.69 ± 1.79 ng/mL, $p < 0.001$ compared to healthy women 0.47 ± 0.06 ng/mL. Furthermore, a significant increase was observed in the values of each estrogen (E2) 18.4 ± 2.19 pg/mL vs. 16.20 ± 3.45 pg/mL, $p = 0.001$, anti-Müllerian hormone (AMH) 15.56 ± 2.88 pmol/L vs. 1.22 ± 0.29 pmol/L, $p < 0.001$, and total oxidant status 2.93 ± 0.63 μ mol/L vs. 0.65 ± 0.09 μ mol/L, $p < 0.001$. On the contrary, a significant decrease in total antioxidant capacity 3.22 ± 0.72 mmol/L vs. 10.04 ± 1.50 mmol/L, $p < 0.001$. The results also show a positive correlation between the values of total oxidants and the hormones studied, compared to the negative correlation with total antioxidants.

Conclusion. The significant increase in the values of ER β as well as the estrogen hormone that may be derived from adipose tissue in women with ovarian cancer in the postmenopausal stage, has multiple effects, for example, by altering some hormones such as progesterone, dehydroepiandrosterone sulfate, testosterone, and AMH. These hormonal disturbances resulting from granulosa cell tumors play a role in increasing the metabolic rate and therefore increasing the oxidative stress of cells.

Keywords. β -estrogen receptors, hormonal disorders, ovarian cancer, oxidative stress, postmenopausal

Introduction

Ovarian cancer affects postmenopausal women and is the second most deadly gynecologic cancer worldwide. About 90% of all ovarian cancers are epithelial ovarian carcinomas, according to histological subgroups.¹ High-grade serous ovarian cancer (HGSOC), the most prevalent and deadly variety, is responsible for 70 to 80% of ovarian cancer fatalities.² This is because the pathology is asymptomatic, which causes the diagnosis to be made after the disease has already advanced and has a poor prognosis. Surgery is typically the first step in treatment and then platinum-based chemotherapy. However, resistance to treatment frequently arises despite early favorable responses, leading to a poor 5-year survival rate of 20% in stage IV and 40% in stage III.³

Estrogen receptor β and ovarian cancer

When estrogen attaches to the ER, receptor dimerization occurs. In the cytoplasm, "ligand-bound ER dimer molecules translocate" to the cell's nucleus. Estrogen receptor elements (ERE) are specific DNA sequences present in the coding regions of target genes to which ER dimers attach in the nucleus.^{4,5} ER-mediated transcriptional regulation causes changes in the expression of specific genes involved in several cellular activities, such as division, growth, survival, and metabolism (Fig. 1). G protein-coupled estrogen receptor 1 (GPER1) is a binding to the membrane protein receptor that binds to estrogen and activates a number of subsequent signaling cascades, including the pathway involving the PI3K, AKT and m and the mitogen-activated protein kinase (MAPK) circuit. This further enhances classical genomic signaling. Rapid cell proliferation, motility, and survival alterations can be caused by this so-called non-genomic signal.^{6,7}




Fig. 1. Impact of estrogen and estrogen receptor on ovarian cancer

Anti-Mullerian hormone and ovarian cancer

The production by the tumor directly causes endocrine symptoms in the majority of cases of granulosa cell tumors (GCTs) cases (two-thirds). Although there are occasional reports of androgenic effects, most of the effects are estrogenic. Menstrual irregularities are observed in premenopausal women, whereas prepubertal women can experience early isosexual development as a result of these effects. Postmenopausal bleeding is the most common symptom among older women. This hormone release has led to a well-documented correlation between GCT and endometrial hyperplasia, as well as adenocarcinoma.⁸ AMH is a highly helpful indicator of cancers originating from granulosa cells of ovarian follicles because it is released

exclusively by these cells in women. According to reports, 76-93% of women with "granulosa cell tumors (folliculomas)" have elevated AMH levels (Fig. 2). AMH levels could be noticeably higher. AMH levels may rise to 16 months before a tumor becomes clinically noticeable. Compared to estradiol and inhibin, AMH appears to be a more specific biomarker for these tumors and its levels are correlated with tumor size.^{9,10} Additionally, AMH is a highly sensitive and specific marker that helps patients with folliculoma who have had the ovaries removed detect a recurrence early. Even 10 to twenty years after the main tumor has been removed, there is a significant chance of recurrence.¹¹




Fig. 2. AMH levels in benign and malignant ovarian cancer in women in the postmenopause phase

Oxidative stress and ovarian cancer

An imbalance between the body's antioxidant defense mechanisms and the generation of reactive metabolites, or free radicals, including oxidants such as reactive nitrogen species (RNS) and reactive oxygen species (ROS), is what leads to oxidative stress (OS). This imbalance may have a cumulative effect and damage biological molecules and cells. Increased oxidant production can lead to an OS state, which can irreversibly damage oxidative biomolecules such as proteins, lipids, and nucleic acids. This OS state is caused by the stimulation of the antioxidant defense mechanism. The development and progression of cancer are closely associated with these lesions. Prior research has indicated that OS has a major impact on the development of cancer.¹² The RNS or ROS can encourage molecular genetic alterations that can accelerate the development and spread of cancers and increase their resistance to treatment (Fig. 1). Although previous studies have explored hormonal disturbances or oxidative stress in ovarian cancer, few have comprehensively investigated the concurrent alterations in estrogen receptor beta (ER β), reproductive hormones, and markers of oxidative stress in postmenopausal women. To our knowledge, this is one of the first case-control studies to examine the integrated relationship between ER β expression, hormonal profiles, and systemic redox status in this patient population.¹²

Aim

The study aims to explain the effect of the presence of estrogen receptors and estrogen hormone in the postmenopausal stage and its effects on disturbances in other hormone levels such as progesterone, testosterone, DHEA, and AMH, as well as high levels of total oxidant status and low levels of antioxidant capacity in women with ovarian cancers compared to healthy women of similar age.

Material and methods

Sample collection and processing

This retrospective study included postmenopausal women diagnosed with ovarian cancer, confirmed by histopathological examination and ultrasound. The patients were age-matched with a control group of healthy women. Blood samples were collected after ethical approval from both the patients and the Iraqi Ministry of Health. Under the supervision of specialist physicians, samples were obtained immediately after diagnosis at the Maternity and Children's Teaching Hospital in Babylon Governorate, Iraq, between February 1 and November 30, 2024. For comparison, blood samples were also taken from healthy controls. Serum was separated from all samples for analysis of hormonal, oxidative stress, and antioxidant parameters.

Study design

The experimental design of this research is a case-control study. Samples were taken from (45) women diagnosed with ovarian cancer after clinical, laboratory, and ultrasound diagnosis, and before starting chemotherapy or radiation therapy to compare with (45) women apparently healthy as control. Patients with chronic diseases or hormonal or endocrine problems were also excluded. The sample size was calculated according to the following equation:

$$n = Z^2 P(1-P)/d^2$$

Ninety samples were gathered; the 'Z score (1.96), the population (0.14)', the number 1 of samples (n), and the absolute marginal error (d), which is equal to 5%, are all indicated.

Inclusion criteria: All women who are suspected of ovarian cancer. Women in the postmenopausal phase.

Exclusion criteria: All women suffering from autoimmune diseases, diabetes mellitus, chronic kidney diseases, hypertension, viral infections such as HPV and any chronic disease. All women with estrogen- or estrogen-like effect therapy.

Procedures

ER β levels were measured using a competitive quantitative ELISA technique (Catalog No: ab285292). The optical density (OD) was measured at 450 nm. The standard curve included the following concentrations: 20, 10, 5, 2.5, 1.25, 0.625, 0.313, and 0 ng/mL.

Serum estradiol concentrations were determined using a competitive ELISA method (Catalog No. E-FS-E117). The OD was measured at 450 nm. The assay had a detection limit of 5 ppb.

Progesterone levels were quantified using a competitive ELISA (Catalog No: EIAP4C21). The OD was read at 450 nm. The assay demonstrated a sensitivity of 47.9 pg/mL, calculated by adding two standard deviations to the mean OD obtained after 20 replicates of the zero standard.

Dehydroepiandrosterone sulfate (DHEA-S) levels were assessed using a competitive immunoluminometric assay on a fully automated chemiluminescence immunoassay (CLIA) analyzer (MAGLUMI system). The assay used an anti-DHEA-S monoclonal antibody labeled with FITC and a purified DHEA-S antigen labeled with ABEI. Each reagent cartridge was equipped with an RFID tag to ensure proper identification and performance. The procedure strictly followed the manufacturer's operating instructions.

Testosterone and AMH: These hormones were measured using an enzyme-linked fluorescent assay based on competitive immunoassay principles. The solid-phase receptacle functioned both as the solid phase and as a pipetting system. All reagents were predispensed in sealed strips and ready to use. The assay was fully automated on the MiniVIDAS® system, with all steps performed by the instrument. The reaction mixture was repeatedly cycled through the SPR to obtain optimal binding and detection.

Total antioxidant capacity (TAC) was measured using the CUPRAC method (Cupric Reducing Antioxidant Capacity), which is based on the redox reaction involving copper (II) ions. The absorbance was recorded at 450 nm using a spectrophotometer. A 1 mM uric acid solution was used as the standard.¹⁴



The total oxidant status (TOS) was determined spectrophotometrically using a method developed by Erel. This technique quantifies total oxidant molecules in serum on their ability to oxidize ferrous ion–o-dianisidine complexes to ferric ions. Glycerol, present in the reaction medium, enhances the oxidation process. In an acidic environment, the resulting ferric ions form a colored complex with xylenol orange. The intensity of the color, measured at 530 nm using a spectrophotometer, is directly proportional to the oxidant concentration in the sample. The assay is calibrated with hydrogen peroxide, and results are expressed in micromolar hydrogen peroxide equivalent per liter ($\mu\text{mol H}_2\text{O}_2 \text{ Eq/L}$).

Statistical analysis

Statistical analysis was done using SPSS version 20 (IBM, Armonk, NY, USA), independent T test and the p-value less than 0.05, and the correlation analysis is performed in Person and (r) is the correlation coefficient. Normal distribution assessed by the Shapiro-Wilk test.

Ethical considerations

The study was approved by the Ethics Committee of the Women's and Maternity Teaching Hospital and Babylon University (IRB No. 2-17, dated February 12, 2024). Informed consent was obtained from all participants.

Results

Table 1 presents the results of female patients with ovarian cancer in terms of age and weight, as well as the results of some of the hormones studied, in addition to the values of total oxidation and total antioxidants.

Table 1. Age, BMI, TOS, TAC, and ER β results in combination with some associated hormones

Parameters	Groups	Means±SD	95% confidence		p
			interval		
			Lower	Upper	
Age (years)	Patients	56.66±3.11	55.77	57.74	0.440
	Control	57.17±3.12	56.27	58.22	
BMI (kg/m²)	Patients	25.92±3.71	24.90	27.12	0.001
	Control	22.43±2.56	21.74	23.24	
ERβ (ng/mL)	Patients	12.69±1.79	12.15	13.42	<0.001
	Control	0.47±0.06	0.45	0.49	
Estrogen (pg/mL)	Patients	18.4±2.19	17.58	19.01	0.001
	Control	16.20±3.45	15.12	17.03	
Progesterone (ng/mL)	Patients	0.82±0.15	0.76	0.87	<0.001
	Control	0.32±0.1	0.28	0.35	
Testosterone (ng/dL)	Patients	7.31±1.21	6.97	7.69	<0.001
	Control	4.07±0.7	3.82	4.30	
DHEA-S (ng/mL)	Patients	1.13±0.22	1.07	1.20	<0.001
	Control	0.66±0.1	0.63	0.70	
AMH (pmol/L)	Patients	15.56±2.88	14.62	16.57	<0.001
	Control	1.22±0.29	1.15	1.29	
TOS (μmol/L)	Patients	2.93±0.63	2.78	3.14	<0.001
	Control	0.65±0.09	0.61	0.68	
TAC (mmol/L)	Patients	3.22±0.72	2.99	3.51	<0.001
	Control	10.04±1.50	10.20	11.80	

The correlation between oxidation antioxidants with the studied hormones, which include estrogen receptors, estrogen, progesterone, testosterone, DHEAs, and AMH, as well as with BMI as shown in (Table 2). There are positive correlations between TOS and BMI, also with the hormones studied. On the contrary, negative correlation for TAC with these parameters.

Table 2. TOS and TAC correlations with ER β and some related hormones^a

Hormones		E β	Estrogen	Progesterone	DHEA-s	Testosterone	AMH	BMI
TOS	r	0.930*	0.904**	0.398**	0.781**	0.836**	0.873**	0.486**
	p	<0.001	<0.001	0.001	<0.001	<0.001	<0.001	<0.001
TAC	r	-0.946**	-0.930**	-0.333**	-0.785**	-0.781**	-0.902**	-0.438**
	p	<0.001	<0.001	0.001	<0.001	<0.001	<0.001	<0.001

^a * The correlation significant at p less than 0.05 (2-tailed), ** – the correlation significant at p less than 0.01 (2-tailed)

There is a positive correlation between estrogen and the beta estrogen receptor with progesterone, DHEA-s, testosterone, and AMH and the results appear in (Table 3).

Table 3. Correlations of estrogen and ER β with some related hormones^a

Hormones		Progesterone	DHEA-s	Testosterone	AMH
Estrogen	r	0.390**	0.267*	0.289**	0.342**
	p	<0.001	0.011	0.001	0.001
ERβ	r	0.877**	0.828**	0.841**	0.944**
	p	<0.001	<0.001	<0.001	<0.001

^a * The correlation significant at p less than 0.05 (2-tailed), ** – the correlation significant at p less than 0.01 (2-tailed)

There is also a positive association between AMH and the hormones studied in women with ovarian cancer (Table 4).

Table 4. Correlations of AMH and related hormones^a

Hormones		ER β	Estrogen	Progesterone	DHEA-s	Testosterone
AMH	r	0.944**	0.342**	0.816**	0.754**	0.703**
	p	<0.001	0.001	<0.001	<0.001	<0.001

^a * The correlation significant at p less than 0.05 (2-tailed), ** – the correlation significant at p less than 0.01 (2-tailed)

Obesity is considered a risk factor for ovarian cancer due to the adipose tissues from estrogen sources. Therefore, a positive correlation between BMI and estrogen, progesterone, DHEA, testosterone, and AMH for women with ovarian cancer in the postmenopausal period (Table 5).

Table 5. Correlations of BMI and related hormones^a

Hormones		ER β	Estrogen	Progesterone	DHEA-s	Testosterone	AMH
BMI	r	0.113	0.463**	0.415**	0.340**	0.386**	0.440**
	p	0.289	<0.001	<0.001	0.001	<0.001	<0.001

^a * The correlation significant at p less than 0.05 (2-tailed), ** – the correlation significant at p less than 0.01 (2-tailed)

Discussion

The notion that postmenopausal obesity is associated with increased mortality from ovarian cancer is supported by the findings of this large prospective investigation. However, among women who were slim and of normal weight, the death rate from ovarian cancer did not increase steadily. Only women who were overweight or obese had a higher risk. As predicted, there was no indication of increased risk with rising BMI between overweight and obese women who had previously taken postmenopausal estrogen.¹⁵

The possible roles of estrogen and androgenic hormones in the development of ovarian cancer provide biological reasons for the relationship between BMI and the death rate from ovarian cancer. After menopause, the main origin of endogenous estrogen is adipose tissue, and postmenopausal women have higher circulating estrogen levels. In the culture of cells from malignant and normal sources, estradiol and estrone promote cell proliferation.¹⁶ Therefore, estrogens of extra glandular origins may encourage ovarian epithelial cells to proliferate and undergo malignant transformation. The documented elevated risk associated with long-term postmenopausal estrogen use lends credence to an estrogen-related role in the development of ovarian cancer. Elevated blood testosterone concentrations have been linked to high BMI

in postmenopausal women. Additionally, in vitro proliferation of both malignant and normal cells is stimulated by testosterone and 5-dihydrotestosterone. In a prospective analysis of blood hormone levels and the appearance of ovarian cancer, prediagnostic levels of androstenedione and dehydroepiandrosterone were linked to an increased risk of ovarian cancer.¹⁷

Granulosa cells in the ovaries are among the human cells that exhibit the highest levels of ER β mRNA and protein expression.¹⁸ This expression is sustained or elevated in granulosa cell tumors of the sex-cord stromal tumor type. However, considering the uncommon granulosa cell malignancies and few cell lines that adequately express this subtype or preserving ER β expression.¹⁹ Therefore, nothing is known about ER β 's functional role of ER in granulosa cell malignancies. Only two studies conducted on this particular subtype in the last five years. The mitochondria of Granulosa tumor cells include a cytoplasmic ER β 2 that binds to the proteins of the 'Bcl2 family' to prevent apoptosis.²⁰ According to a different study, when ER α is present, ER β promotes tumor growth. Both results suggest that ER β plays a tumor-promoting function in these malignancies, albeit through different methods. These results highlight the need for a more thorough comprehension of ER β and its isoforms in granulosa cells.²¹

Like certain tumor suppressor transcripts, ER β 's mRNA may be quickly destroyed if it functions as a tumor suppressor.²² However, to ascertain the expression of a protein, validation using a non-antibody-dependent technique is necessary. According to several findings, ER β in particular, normal tissues, may prevent the occurrence of cancer, as it is linked to enhanced apoptosis, decreased cell proliferation, and anti-inflammatory qualities when present and activated.²²

An analysis of ER β and its function in malignant neoplasms requires navigating a difficult and demanding field characterized by disagreements, variant-specific roles, and structural complexity. A vital component of researching ER β is the use of antibodies in organs with minimal to non-existent protein expression. Since each isoform may have a different impact on its activity, the complex interaction between ER β subtypes and their cellular location adds even another dimension to their functional variety. It is worth mentioning that antibodies directed against neglected tropical diseases (NTD) would identify every variation of ER β rather than discriminate between distinct isoforms.²³ High levels of estrogen and progesterone receptor activation are frequently associated with LGSOC. Furthermore, they typically exhibit a wild-type expression pattern, in contrast to individuals with HGSOC, and active mitogen-activated protein kinase (MAPK) pathways with KRAS and BRAF mutations.²⁴

Rare ovarian cancers known as Sertoli-Leydig cell tumors (SLCT) are triggered by stromal cells and rudimentary sex cords in the ovary. These tumors usually appear during the second and fourth decades of life and account for fewer than 0.5% of ovarian malignancies. The self-secretion of testosterone or its precursor androstenedione, by several of these tumors induces a significant androgen excess in females. The remaining tumors either do not function at all or produce estrogen. Because SLCT is so rare, knowledge of its prognostic variables is rather poor.²⁵ Numerous investigations have noted that the most important

prognostic factors are tumor stage at assessment and level of differentiation.²⁶ Serum testosterone often indicates the amount of androgen produced by the ovaries in women. Adrenal androgens, such as androstenedione, are converted to a minor amount of testosterone. Adrenocortical carcinoma is known to cause markedly high serum testosterone levels, which are correlated with circulating precursor substances of adrenal androgen precursor substances.²⁷

About 10% of all ovarian tumors are stromal neoplasms of the sex cord, which are formed from mesenchymal stem cells found in the ovarian cortex. These consist of Sertoli–Leydig cell tumors, granulosa–theca cell tumors, and granulosa cell tumors (GCT). Three percent of ovarian tumors are GCTs. Based on histological characteristics and clinical presentation, two different forms of GCT have been identified, the pediatric and adult form have been identified.²⁸

The elevation of serum AMH for patients with GCT because of gene expression of neoplasm specimens. AMH expression was found in each of the GC tumors in a limited number of ovarian tumors, but was absent in the seven epithelial carcinomas. Although AMH positivity was consistently detectable in the GC tumors, it did not appear as prominent or diffuse in alpha-inhibin employing paraffin-fixed tissues and an antibody directed against AMH. It has recently been confirmed that AMH expression can be found in young and adult-type GCT regardless of the ovarian or metastatic location.^{29–31}

Recently, it has been discovered that human ovarian epithelial cancer expresses AMH type II receptors (AMH-RII). AMH-RII mRNA was detected by RT-PCR in ovarian cancer cells and peritoneal cells in those suffering from ovarian papillary squamous cystadenocancer. Ten out of the 15 patients had cell lines with AMH-RII transcripts. The existence of AMH-RII mRNA predicted binding to AMH in 89% of the cases. AMH-RII immunostaining was also shown in the solid tumors of four individuals.^{32–34}

According to studies, the Fenton reaction is how ferrous and its metabolites increase the creation of ROS. Old blood from the ovary, which has an exceptionally high iron concentration during the development of the chocolate cyst, might increase ROS creation of ROS and cause DNA damage, hence raising the likelihood of the endometriosis turning malignantly into mast cell ovarian cancer.^{35–38} The transferrin receptor 1 (TfR1) axis is boosted by the hydroxyl radicals created via H_2O_2 in the “Fenton reaction”. This can result in many double-strand breaks in the DNA of the oviduct's epithelial cells, which will encourage OV. Furthermore, OS affects different immune cells, including regulatory T cells, myeloid-derived suppressor cells, neutrophils, and tumor-associated macrophages. Our findings expand current knowledge by demonstrating strong correlations between $ER\beta$ and multiple hormonal and oxidative stress parameters, which may reflect a mechanistic link between estrogen signaling and redox imbalance in the tumor microenvironment. Unlike previous studies that focused on isolated markers, this investigation combines endocrine and oxidative markers, offering a more integrative perspective on tumor biology in postmenopausal ovarian cancer.^{39,40}

Study limitations

Despite the study's thoroughness, numerous aspects remain unexplored and could be investigated in future research. These include taking into account the duration of the illness and reviewing patient follow-ups both before and after the prescription of antioxidants and vitamins supplements. Furthermore, the patient's lifestyle was neglected because it is integrally related to behavior, decisions about life, and food, all of which have a strong connection with elevated oxidative stress levels.

Conclusion

This study provides novel insights into the interplay between ER β , hormonal dysregulation, and oxidative stress in postmenopausal women with ovarian cancer, highlighting the potential of ER β and AMH as candidate biomarkers for future diagnostic and prognostic applications. Hormonal disturbances in postmenopausal women can contribute to the occurrence of ovarian cancer in women. A large percentage of these women who have ovarian cancer have positive estrogen receptors. Estrogen at this age plays a role in increasing the growth rate of granulosa cell tumors. These tumor cells play a role in increasing the levels of estrogen, DHEA, testosterone, and AMH. These hormonal disturbances in granulosa cell tumors increase metabolic processes and thus increase oxidation levels due to mitochondrial activity and the electron transport chain, which in turn leads to a decrease in the total concentrations of antioxidants in patients. Weight gain in postmenopausal women can also be considered a risk factor for ovarian cancer. Because adipose tissue is a source of estrogen production, which is a risk factor after binding to the estrogen receptors alpha and beta, which in turn disrupts the body's hormones and balance of oxidant-antioxidants.

Acknowledgments

The authors thank the patients at the Maternity and Children's Teaching Hospital in Babylon Governorate, Iraq, and the medical staff who helped us in this research.

Declarations

Funding

Funding was not acquired.

Author contributions

Conceptualization, A.M.A.A-K.; Methodology, N.J.T.A-M.; Software, N.J.T.A-M.; Validation, A.M.A.A-K. and N.J.T.A-M.; Formal Analysis, N.J.T.A-M.; Investigation, A.M.A.A-K.; Resources, A.M.A.A-K.; Data Curation, N.J.T.A-M.; Writing – Original Draft Preparation, A.M.A.A-K.; Writing – Review & Editing, A.M.A.A-K.; Visualization, A.M.A.A-K.; Supervision, A.M.A.A-K.; Project Administration, A.M.A.A-K.; Funding Acquisition, N.J.T.A-M..

Conflicts of interest

There are no conflicts of interest.

Data availability

The corresponding author can be contacted for the raw data upon request.

Ethics approval

The study was approved by the Ethics Committee of the Women's and Maternity Teaching Hospital and Babylon University (IRB No. 2-17, dated February 12, 2024).

References

1. Li Y, Song W, Gao P, et al. Global, regional, and national burden of breast, cervical, uterine, and ovarian cancer and their risk factors among women from 1990 to 2021, and projections to 2050: findings from the global burden of disease study 2021. *BMC Cancer*. 2025;25(1):330. doi: 10.1186/s12885-025-13741-9
2. Subramanian DN, Zethoven M, Pishas KI, et al. Assessment of candidate high-grade serous ovarian carcinoma predisposition genes through integrated germline and tumour sequencing. *NPJ Genomic Med*. 2025;10(1):1. doi: 10.1038/s41525-024-00447-3
3. Punzón-Jiménez P, Lago V, Domingo S, Simón C, Mas A. Molecular management of high-grade serous ovarian carcinoma. *Int J Mol Sci*. 2022;23(22):1-30. doi: 10.3390/ijms232213777
4. Zhang Q, Li Y, Li J, Ma J, Li M, Guo LH. A Fluorescence Biosensor with a Dual-function DNA Probe Targeting the Activated Estrogen Receptor for Estrogenic Activity Evaluation. *Environ Res*. 2025;273(1):121-163. doi: 10.1016/j.envres.2025.121163
5. Lutz PB, Coombs WR, Bayse CA. Determination of Structural Factors Contributing to Protection of Zinc Fingers in Estrogen Receptor α through Molecular Dynamic Simulations. *J Phys Chem B*. 2025;129(8):2226-2234. doi: 10.1021/acs.jpcc.4c05730
6. Bhatia N, Kumar S, Goyal LD, Thareja S. Optimizing selective estrogen receptor degraders for anticancer drug development. *Future Med Chem*. 2025;17(6):637-640. doi: 10.1080/17568919.2025.2467615
7. Clusan L, Ferrière F, Flouriot G, Pakdel F. A basic review on estrogen receptor signaling pathways in breast cancer. *Int J Mol Sci*. 2023;24(7):6834. doi: 10.3390/ijms24076834
8. Ünal Ç, Ordu Ç, Özmen T, et al. Evaluation of Anti-Mullerian Hormone Levels, Antral Follicle Counts, and Mean Ovarian Volumes in Chemotherapy-Induced Amenorrhea among Breast Cancer Patients: A Prospective Clinical Study. *Curr Oncol*. 2023;30(10):9217-9229. doi:

9. Jovičić S, Plebani M. Biomarkers of menopause. *Arch Pharm.* 2025;75(1):1-14. doi: 10.5937/arhfarm75-55314
10. Cetin N, Koca D. Anti-Müllerian Hormone Concentrations Can Be Reliably Determined by a Single Measurement, Irrespective of Cycle, in Synchronised Ewes During Non-Breeding Season. *Reprod Domest Anim.* 2025;60(2):1-6. doi: 10.1111/rda.70010
11. Karkanaki A, Vosnakis C, Panidis D. The clinical significance of anti-Müllerian hormone evaluation in gynecological endocrinology. *Hormones.* 2011;10(2):95-103.
12. Mukherjee S, Nag S, Mukerjee N, et al. Unlocking exosome-based theragnostic signatures: deciphering secrets of ovarian cancer metastasis. *ACS Omega.* 2023;8(40):36614-36627. doi: 10.1021/acsomega.3c02837
13. Rajan N, Debnath S, Perveen K, et al. Optimizing hybrid vigor: a comprehensive analysis of genetic distance and heterosis in eggplant landraces. *Front Plant Sci.* 2023;14(1):1238870. doi: 10.3389/fpls.2023.1238870
14. Tufan AN, Çelik SE, Özyürek M, Güçlü K, Apak R. Direct measurement of total antioxidant capacity of cereals: QUENCHER-CUPRAC method. *Talanta.* 2013;108(1):136-142. doi: 10.1016/j.talanta.2013.02.061
15. Kiesel L, Eichbaum C, Baumeier A, Eichbaum M. Obesity epidemic—the underestimated risk of endometrial cancer. *Cancers (Basel).* 2020;12(12):3860. doi: 10.3390/cancers12123860
16. Leeners B, Geary N, Tobler PN, Asarian L. Ovarian hormones and obesity. *Hum Reprod Update.* 2017;23(3):300-321. doi: 10.1093/humupd/dmw045
17. Dallal CM, Lacey J V, Pfeiffer RM, et al. Estrogen metabolism and risk of postmenopausal endometrial and ovarian cancer: the B~ FIT cohort. *Horm Cancer.* 2016;7(1):49-64. doi: 10.1007/s12672-015-0237-y
18. Luc K, Schramm-Luc A, Guzik TJ, Mikolajczyk TP. Oxidative stress and inflammatory markers in prediabetes and diabetes. *J Physiol Pharmacol.* 2019;70(6):111-113. doi: 10.1038/ncomms15840
19. Birgersson M, Indukuri R, Antonson P, Nalvarte I, Archer A, Williams C. ER β in granulosa cell tumors and its clinical potential. *Endocrinology.* 2023;164(6):bqad063. doi: 10.1210/endocr/bqad063
20. Ciucci A, Ferrandina G, Mascilini F, et al. Estrogen receptor β : Potential target for therapy in adult granulosa cell tumors? *Gynecol Oncol.* 2018;150(1):158-165. doi: 10.1016/j.ygyno.2018.05.013
21. Cluzet V, Devillers MM, Petit F, et al. Estradiol promotes cell survival and induces Greb1 expression in granulosa cell tumors of the ovary through an ER α -dependent mechanism. *J Pathol.* 2022;256(3):335-348. doi: 10.1002/path.5843
22. Gao X, Yi Y, Lv J, et al. Low RNA stability signifies strong expression regulatability of tumor

- suppressors. *Nucleic Acids Res.* 2023;51(21):11534-11548. doi: 10.1093/nar/gkad838
23. Khan D, Ansar Ahmed S. The immune system is a natural target for estrogen action: opposing effects of estrogen in two prototypical autoimmune diseases. *Front Immunol.* 2016;6(1):1-8. doi: 10.3389/fimmu.2015.00635
 24. Zwimpfer TA, Tal O, Geissler F, et al. Low grade serous ovarian cancer—a rare disease with increasing therapeutic options. *Cancer Treat Rev.* 2023;112(1):102497. doi: 10.1016/j.ctrv.2022.102497
 25. Wang G, Zhang R, Li C, Chen A. Characteristics and outcomes analysis of ovarian Sertoli–Leydig cell tumors (SLCTs): analysis of 15 patients. *J Ovarian Res.* 2021;14(1):150. doi: 10.1186/s13048-021-00909-7
 26. Akman L, Ertas IE, Gokcu M, et al. Ovarian sertoli–leydig cell tumors: A multicenter long-term clinicopathological analysis of 27 patients. *J Cancer Res Ther.* 2016;12(1):290-294. doi: 10.4103/0973-1482.158037
 27. Nef J, Huber DE. Ovarian Sertoli–Leydig cell tumours: A systematic review of relapsed cases. *Eur J Obstet Gynecol Reprod Biol.* 2021;263(1):261-274. doi: 10.1016/j.ejogrb.2021.06.036
 28. Durlinger A, Visser J, Themmen A. Regulation of ovarian function: the role of anti-Mullerian hormone. *Reproduction.* 2002;124(1):601-609.
 29. Friedlander ML, Anderson L, Lee YC. Controversies in the management of ovarian granulosa cell and Sertoli-Leydig cell tumors. *Int J Gynecol Cancer.* 2025;35(3):101668. doi: 10.1016/j.ijgc.2025.101668
 30. Xu S, Hu D, Ye Y, Mu Y, Xiong Y, Zhang Y. Identification of serum small non-coding RNA as biomarkers for endometrial receptivity. *Genomics.* 2025;117(2):111002. doi: 10.1016/j.ygeno.2025.111002
 31. de Vet A, Laven JSE, de Jong FH, Themmen APN, Fauser BCJM. Antimüllerian hormone serum levels: a putative marker for ovarian aging. *Fertil Steril.* 2002;77(2):357-362. doi: 10.1016/S0015-0282(01)02993-4
 32. Chester M, Devillers MM, Corre R, et al. Reduction in minipubertal gonadotropin levels alters reproductive lifespan and ovarian follicular loss in female mice. *Hum Reprod.* 2025;40(4):717-729. doi: 10.1093/humrep/deaf019
 33. Koinuma Y, Mitsuishi Y, Winardi W, et al. Anti-Müllerian hormone type II receptor protein expression in non-small cell lung cancer and the effect of AMH/AMHR2 signaling on cancer cell proliferation. *Thorac Cancer.* 2024;15(29):2090-2099. doi: 10.1111/1759-7714.15309
 34. Chin T, Parry RL, Donahoe PK. Human müllerian inhibiting substance inhibits tumor growth in vitro and in vivo. *Cancer Res.* 1991;51(8):2101-2106.
 35. Zhang Y, Zou L, Li X, et al. SLC40A1 in iron metabolism, ferroptosis, and disease: a review. *WIREs*

Mech Dis. 2024;16(4):1-8. doi: 10.1002/wsbm.1644

36. Sui X, Wang J, Zhao Z, et al. Phenolic compounds induce ferroptosis-like death by promoting hydroxyl radical generation in the Fenton reaction. *Commun Biol.* 2024;7(1):199. doi: 10.1038/s42003-024-05903-5
37. Chen L, Shen Q, Liu Y, et al. Homeostasis and metabolism of iron and other metal ions in neurodegenerative diseases. *Signal Transduct Target Ther.* 2025;10(1):31. doi: 10.1038/s41392-024-02071-0
38. Amano T, Murakami A, Murakami T, Chano T. Antioxidants and therapeutic targets in ovarian clear cell carcinoma. *Antioxidants.* 2021;10(2):187. doi: 10.3390/antiox10020187
39. He J, Liu Y, Wang X, et al. The impact of radiation dose to immune cells in stage IV non-small cell lung cancer in the era of immunotherapy. *Clin Lung Cancer.* 2025;26(3):221-227. doi: 10.1016/j.clcc.2025.02.006
40. Ding DN, Xie LZ, Shen Y, et al. Insights into the role of oxidative stress in ovarian cancer. *Oxid Med Cell Longev.* 2021;2021(1):8388258. doi: 10.1155/2021/8388258